Sorafenib is a multikinase inhibitor with activity against angiogenesis and the RAF-MEK-ERK pathway; it inhibited the proliferation of human gastric cancer cell line, and may reverse resistance to cisplatin by downregulating MDR1 expression [51]. The gene discussed is MAP2K7; the disease is gastric cancer.